Guidance Boosted
Medtronic Raises Fiscal 27 Guidance After Posting Strong First Quarter Revenue Growth
Anonymous
Key Points
1
Detailed Q1 FY27 portfolio breakdown shows cardiovascular revenue of about $3.927 billion (up 18.9% organic), neuroscience about $2.678 billion (up 9.3% organic), medical-surgical about $2.279 billion (up 10.2% organic), and diabetes about $843 million (up 14.9% organic).
2
Quarterly margins show GAAP gross margin at 65.0%, GAAP operating margin at 18.1%, and non-GAAP operating margin at 23.7%.
3
Cornerstone Robotics expansion includes secured distribution rights for the Sentire surgical system in markets outside the United States, Sentire to be offered alongside Hugo, with Hugo deployed in more than 35 countries and the year expected to exceed 50,000 robotic procedures.
4
Other strategic moves include the completed acquisitions of Scientia Vascular and SPR Therapeutics, plus FDA clearance for the Touch Surgery Aide next-generation platform, underscoring Medtronic's broader growth initiatives.
5
Diabetes segment revenue was $843 million, up 16.9% reported and 14.9% organic, with the note that the diabetes business continues to be separated from the overall portfolio through capital markets transactions.
Medtronic reported first-quarter FY27 revenue of $9.756 billion, up 13.7% year over year, and raised its full-year guidance on strong operating performance across all four business units. The company lifted its organic revenue growth forecast to 7.25%–7.75% and adjusted EPS guidance to $5.94–$6.00, signaling confidence in its growth trajectory TS2 Tech.
The boost came as Medtronic announced $700 million in new robotics investments and up to $80 million in cardiac technology partnerships, with options to expand its surgical robotics footprint globally. Shares climbed 3.2% to $93.56 following the upbeat earnings and strategic moves TS2 Tech.
Cardiovascular Unit Powers Strong Quarterly Growth
Cardiovascular revenue hit $3.93 billion, up 18.9% on an organic basis, driven by surging demand in electrophysiology and cardiac rhythm management. Cardiac ablation surged 88%, reflecting strong adoption of Medtronic's advanced heart-rhythm solutions BigGo Finance.
The cardiovascular segment accounts for 40% of quarterly revenue. Neuroscience added $2.68 billion (up 9.3% organic), while medical-surgical contributed $2.28 billion (up 10.2% organic), demonstrating balanced strength across the company's core businesses Investing.
$700 Million Robotics Push Targets International Expansion
Medtronic is investing $700 million through Cornerstone Robotics to expand surgical robotics distribution globally. The company secured rights to distribute the Sentire surgical system outside the US, offering it alongside its Hugo robotic platform, already deployed in over 35 countries TS2 Tech.
This year is expected to exceed 50,000 robotic procedures. The push reflects Medtronic's bid to capture growing demand for minimally invasive surgical tools in markets beyond North America TS2 Tech.
Diabetes and Cardiac Technology Deals Accelerate Growth
Diabetes revenue climbed to $843 million, up 14.9% organically, as Medtronic pushes to separate and grow this high-margin segment. The company committed up to $80 million to Pi-Cardia, a cardiac technology firm, with an option to acquire it for roughly $210 million Market Screener.
Medtronic also completed acquisitions of Scientia Vascular and SPR Therapeutics while securing FDA clearance for Touch Surgery Aide, a next-generation surgical planning platform. These moves underscore management's focus on expanding its surgical and device portfolios Trading View.
Margins Improve as Company Demonstrates Operating Discipline
Non-GAAP operating margin expanded to 23.7%, and non-GAAP EPS reached $1.45 in the quarter. GAAP gross margin held steady at 65.0%, reflecting disciplined cost management and pricing power across all segments Trading View.
The fiscal 2027 year contains 53 weeks instead of the typical 52, contributing an estimated $570 million to organic revenue growth in Q1 alone. Management's decision to raise guidance demonstrates confidence that operational momentum will extend through the full year Investing.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
37
Reach
47
A
AnonymousAuthor
